Papers by Markku J Kauppi
Scandinavian Journal of Rheumatology, 1999
ABSTRACT An inception cohort of 74 patients with seropositive and erosive RA were followed up for... more ABSTRACT An inception cohort of 74 patients with seropositive and erosive RA were followed up for 15 years. All 148 shoulders were radiographed with a standard method at the 15-year follow-up. The coracoclavicular region was evaluated from each radiograph. In addition, the distance between the processus coracoideus and the superior margin of the clavicle was measured. Only one clavicle had elongated, shallow erosion on the undersurface at the insertion area of the coracoclavicular ligaments. In this case the distance between the coracoid process and clavicle was 25 mm, whereas the mean distance of all shoulders (n=148) was 17.4 mm (range 9-25 mm). We conclude that resorption on the undersurface of the distal clavicle is an atypical manifestation in rheumatoid arthritis. The origin of this atypical lesion is a not diminished distance between the processus coracoideus and the clavicle. Inflammation of the coracoclavicular ligaments is most likely the reason for this lesion.
Bookmarks Related papers MentionsView impact
Scandinavian Journal of Rheumatology, 1999
Bookmarks Related papers MentionsView impact
PubMed, Mar 31, 2009
Objective: Our aim was to evaluate how frequently problems of quality and quantity of sleep and d... more Objective: Our aim was to evaluate how frequently problems of quality and quantity of sleep and depression occur in patients with fibromyalgia (FM), and compare these findings with those occurring in patients with rheumatoid arthritis (RA) and in the general population. Materials and methods: The patients were recruited from rehabilitation courses in the Rheumatism Foundation Hospital, Finland. There were 37 patients with FM and 31 patients with RA participating in the study. For comparison, we used the results from a general population study of 1284 adult subjects. The data had been collected earlier in a longitudinal cohort study for the Finnish Social Insurance Institution. Results: The patients with FM and RA slept fewer hours a day than the population sample. The FM patients reported more insomnia, less contentment with sleep and more lack of deep and restful sleep in comparison to the RA patients and the participants of the population study. The FM patients also reported significantly more depression and pain than the RA patients (p0.01). It was still shown in a logistic regression analysis that insomnia was almost five times more frequent in FM patients than in RA patients, even when depression and pain were adjusted. Conclusion: The FM patients reported more insomnia-related symptoms than either RA patients or the population sample. The higher prevalence of insomnia-related symptoms among FM patients was not explained by depression or pain. Both patient groups reported somewhat shorter nocturnal sleep than the general population.
Bookmarks Related papers MentionsView impact
Joint Bone Spine, Dec 1, 2002
Bookmarks Related papers MentionsView impact
Clinical Rheumatology, May 1, 2002
Bookmarks Related papers MentionsView impact
Scandinavian Journal of Rheumatology, 1996
Bookmarks Related papers MentionsView impact
Rheumatology Advances in Practice, 2023
Bookmarks Related papers MentionsView impact
Annals of the Rheumatic Diseases, Apr 1, 2001
Bookmarks Related papers MentionsView impact
Journal of Arthroplasty, Feb 1, 2000
Bookmarks Related papers MentionsView impact
Clinical Rheumatology, 2015
Autoreactive B cells infected by Epstein-Barr virus (EBV) are suspected to be involved in the eti... more Autoreactive B cells infected by Epstein-Barr virus (EBV) are suspected to be involved in the etiology of various human chronic autoimmune diseases. This motivated us to study the relationship between peripheral blood EBV load at baseline and treatment response to B cell-depleting therapy in rheumatoid arthritis (RA) patients. Thirty-five RA patients who started treatment with rituximab (RTX) in a routine clinical setting were assessed for baseline disease activity using disease activity score using 28 joint counts (DAS28) (erythrocyte sedimentation rate [ESR]). Treatment response was evaluated 3-7 months after RTX. EBV load in baseline whole blood (WB) samples was determined using quantitative PCR. EBV DNA was detected in 16/35 (46 %) of the WB samples. In these 16 EBV-positive patients, the median viral load was 3.15 (2.68-4.00) log copies/ml. Good/moderate European League Against Rheumatism (EULAR) response was observed in 16/16 of the EBV DNA-positive vs 13/19 EBV DNA-negative patients, p = 0.022. Significant response (DAS28 change >1.2) was observed in 14/16 of the EBV DNA-positive vs 10/19 EBV DNA-negative patients, p = 0.035. The decline in DAS28 after RTX was 2.10 (1.03-4. 78) in the EBV DNA-positive vs 1.47 (-0.7-4.70) in the EBV DNA-negative patients, p = 0.13. EBV load at baseline significantly correlated with change in DAS28 after RTX (τB = -0.261, p = 0.042). Our results suggest that the presence of EBV genome in WB could serve as a predictive marker to RTX therapy in RA.
Bookmarks Related papers MentionsView impact
Bookmarks Related papers MentionsView impact
Annals of the Rheumatic Diseases, 1999
Bookmarks Related papers MentionsView impact
Annals of the Rheumatic Diseases, 2002
Bookmarks Related papers MentionsView impact
Scandinavian Journal of Rheumatology, Jan 11, 2022
OBJECTIVE To estimate the prevalence of psoriatic arthritis (PsA), axial spondyloarthritis (axSpA... more OBJECTIVE To estimate the prevalence of psoriatic arthritis (PsA), axial spondyloarthritis (axSpA) and rheumatoid arthritis (RA) and the use of biologic agents in these diseases in Norway. METHODS From the Norwegian Patient Registry (NPR), we identified as PsA, axSpA and RA patients ≥18 years those with ≥2 recorded episodes with diagnostic coding for index disease (L40.5, M07.0-M07.3 for PsA; M45, M46.0, M46.1, M46.8 and M46.9 for axSpA; M05-M06 for RA). We calculated the point prevalence of PsA, axSpA and RA as per the 1st of January 2017 in the Norwegian adult population (age ≥18). Dispensed disease-modifying antirheumatic drug (DMARD) prescriptions were obtained from the Norwegian Prescription Database and biologic DMARDs given in hospitals from the NPR. RESULTS The point prevalence of PsA, axSpA, RA, and any of these diseases in total was 0.46%, 0.41%, 0.78%, and 1.56%, respectively. Among women, the prevalence of PsA, axSpA, and RA was 0.50%, 0.37%, and 1.10%, and among men 0.43%, 0.45%, and 0.46%, respectively. In 2017, 27.3% of RA patients, 25.7% of PsA patients and 35.1% of axSpA patients used biologic DMARDs. Treatment with biologics was more frequent in younger age groups in all three diseases, and became more infrequent especially after age ≥55 years. CONCLUSION In Norway, the combined prevalence of PsA, axSpA, and RA was over 1.5%. Reflecting the good overall access to highly effective but costly biologic treatments, more than a fourth of these patients used biologic agents, which corresponds to over 0.4% of Norwegian adult population.
Bookmarks Related papers MentionsView impact
Scandinavian Journal of Rheumatology, 2019
Bookmarks Related papers MentionsView impact
BMJ Open
ObjectiveTo establish the prevalence of hyperuricaemia in an elderly Finnish cohort and to assess... more ObjectiveTo establish the prevalence of hyperuricaemia in an elderly Finnish cohort and to assess its association with comorbidities and mortality.DesignProspective cohort study.SettingGood Ageing in Lahti Region study, Finland 2002–2012 (mortality data analysed until 2018).Participants2673 participants (mean age 64 years; 47% men).Primary and secondary outcome measuresPrevalence of hyperuricaemia in the study population was detected. Associations between hyperuricaemia and mortality were assessed using multivariable adjusted Cox proportional hazards models.MethodsData from a prospective, population-based study of elderly people (52–76 years) in the Lahti region, Finland, were used. Information on serum uric acid (SUA) levels as well as several other laboratory variables, comorbidities, lifestyle habits and socioeconomic factors was collected, and the association between SUA level and mortality in a 15-year follow-up period was analysed.ResultsOf 2673 elderly Finnish persons include...
Bookmarks Related papers MentionsView impact
Scandinavian Journal of Rheumatology, Sep 13, 2021
Bookmarks Related papers MentionsView impact
Annals of the Rheumatic Diseases, 2013
Bookmarks Related papers MentionsView impact
BMJ Open
ObjectiveTo establish the prevalence of hyperuricaemia in an elderly Finnish cohort and to assess... more ObjectiveTo establish the prevalence of hyperuricaemia in an elderly Finnish cohort and to assess its association with comorbidities and mortality.DesignProspective cohort study.SettingGood Ageing in Lahti Region study, Finland 2002–2012 (mortality data analysed until 2018).Participants2673 participants (mean age 64 years; 47% men).Primary and secondary outcome measuresPrevalence of hyperuricaemia in the study population was detected. Associations between hyperuricaemia and mortality were assessed using multivariable adjusted Cox proportional hazards models.MethodsData from a prospective, population-based study of elderly people (52–76 years) in the Lahti region, Finland, were used. Information on serum uric acid (SUA) levels as well as several other laboratory variables, comorbidities, lifestyle habits and socioeconomic factors was collected, and the association between SUA level and mortality in a 15-year follow-up period was analysed.ResultsOf 2673 elderly Finnish persons include...
Bookmarks Related papers MentionsView impact
Clinical and experimental rheumatology, 2019
Bookmarks Related papers MentionsView impact
Uploads
Papers by Markku J Kauppi